Table 3.
Drug selection strategy for PD patients under specific circumstances among doctors from different levels of hospitals and cities
| Items | Non-tertiary hospitals (n=147) | Tertiary hospitals (n=342) | Pvalue | Non-capital cities (n=259) | Capital cities (n=230) | P value |
|---|---|---|---|---|---|---|
| Age < 65 years without cognitive impairment | ||||||
| Levodopa |
60(40.8%) |
104(30.4%) |
0.025 |
102(39.4%) |
62(27.0%) |
0.004 |
| Dopamine agonists |
47(32.0%) |
163(47.7%) |
0.001 |
77(29.7%) |
133(57.8%) |
0.000 |
| MAO-B inhibitors |
15(10.2%) |
47(13.7%) |
0.282 |
22(8.5%) |
40(17.4%) |
0.003 |
| Age > 65 years or with cognitive impairment | ||||||
| Levodopa |
86(58.5%) |
191(55.8%) |
0.587 |
127(49.0%) |
150(65.2%) |
0.000 |
| Dopamine agonists |
17(11.6%) |
97(28.4%) |
0.000 |
45(17.4%) |
69(30.0%) |
0.001 |
| MAO-B inhibitors |
12(8.2%) |
29(8.5%) |
0.908 |
19(7.3%) |
22(9.6%) |
0.375 |
| Wearing-off phenomenon |
|
|
|
|
|
|
| Add levodopa frequency |
44(29.9%) |
143(41.8%) |
0.013 |
67(25.9%) |
120(52.2%) |
0.000 |
| Switch to CR levodopa |
67(45.6%) |
169(49.4%) |
0.436 |
106(40.9%) |
130(56.5%) |
0.001 |
| Add COMT or MAO-B inhibitors |
54(36.7%) |
149(43.6%) |
0.160 |
85(32.8%) |
118(51.3%) |
0.000 |
| Add dopamine agonists |
58(39.5%) |
138(40.4%) |
0.853 |
81(31.3%) |
115(50.0%) |
0.000 |
| Peak-dose dyskinesia |
|
|
|
|
|
|
| Reduce levodopa dose, add its frequency |
55(37.4%) |
163(47.7%) |
0.037 |
91(35.1%) |
127(55.2%) |
0.000 |
| Reduce levodopa dose, add dopamine agonists |
58(39.5%) |
157(45.9%) |
0.188 |
97(37.5%) |
118(51.3%) |
0.002 |
| Reduce levodopa dose, add COMT inhibitors |
41(27.9%) |
104(30.4%) |
0.576 |
60(23.2%) |
85(37.0%) |
0.001 |
| Add amantadine |
17(11.6%) |
54(15.8%) |
0.224 |
31(12.0%) |
40(17.4%) |
0.089 |
| PD with psychosis |
|
|
|
|
|
|
| Clozapine |
31(21.1%) |
81(23.7%) |
0.531 |
41(15.8%) |
71(30.9%) |
0.000 |
| Olanzapine |
59(40.1%) |
165(48.2%) |
0.099 |
98(37.8%) |
126(54.8%) |
0.000 |
| Quetiapine |
16(10.9%) |
90(26.3%) |
0.000 |
32(12.4%) |
74(32.2%) |
0.000 |
| PD with dementia |
|
|
|
|
|
|
| Huperzine A |
51(34.7%) |
73(21.3%) |
0.002 |
53(20.5%) |
71(30.9%) |
0.008 |
| Donepezil |
70(47.6%) |
193(56.4%) |
0.073 |
126(48.6%) |
137(59.6%) |
0.016 |
| Rivastigmine |
15(10.2%) |
67(19.6%) |
0.011 |
41(15.8%) |
41(17.8%) |
0.555 |
| Memantine |
32(21.8%) |
153(44.7%) |
0.000 |
61(23.6%) |
124(53.9%) |
0.000 |
| PD with depression |
|
|
|
|
|
|
| Tricyclic antidepressants |
41(27.9%) |
60(17.5%) |
0.010 |
65(25.1%) |
36(15.7%) |
0.010 |
| SSRIs |
86(58.5%) |
206(60.2%) |
0.721 |
144(55.6%) |
148(64.3%) |
0.049 |
| Pramipexole |
40(27.2%) |
145(42.4%) |
0.001 |
62(23.9%) |
123(53.5%) |
0.000 |
| PD with RLS |
|
|
|
|
|
|
| Levodopa |
31(21.1%) |
92(26.9%) |
0.174 |
48(18.5%) |
75(32.6%) |
0.000 |
| Dopamine agonists |
31(21.1%) |
118(34.5%) |
0.003 |
56(21.6%) |
93(40.4%) |
0.000 |
| Benzodiazepines | 43(29.3%) | 97(28.4%) | 0.842 | 88(34.0%) | 52(22.6%) | 0.006 |